All In Biotech

Drug Trial Radar · NCT06874010

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Patients With Friedreich's Ataxia

Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jun 2025

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Lead sponsor
Design Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.

Conditions

  • Friedreich Ataxia

Interventions

  • DT-216P2Drug

    Active

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of treatment-emergent adverse events (TEAE)Time frame: Up to Week 12

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research Ltd

    Sydney, New South Wales, Australia · Recruiting

  • Doherty Clinical Trials

    East Melbourne, Victoria, Australia · Recruiting

  • Nucleus Network

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.